For patients with advanced melanoma — including acral and mucosal subtypes — GC101 TIL therapy offers a new option when PD-1 therapy has failed.
Unlike in Western countries where cutaneous melanoma accounts for over 90% of cases, melanoma in China and other Asian populations has a very different distribution.
Acral and mucosal melanomas have lower tumor mutational burden (TMB) than cutaneous melanoma, making them less visible to PD-1 checkpoint inhibitors. China accounts for only 2.7% of global melanoma cases but 9.2% of global melanoma deaths — mortality is 3.4× the global average, largely due to more aggressive subtypes.
The standard pathway — PD-1 inhibitors → chemotherapy → limited options — is especially inadequate for acral and mucosal subtypes. TIL therapy addresses this differently: rather than broadly activating the immune system, it amplifies existing tumor-specific T cells that already recognize the patient's unique tumor antigens.
The MIZAR-003 Phase II randomized controlled trial, led by Prof. Jun Guo (郭军) at Peking University Cancer Hospital, is the largest TIL therapy study in melanoma reported to date with a focus on Asian-predominant subtypes.
ASCO 2026 Late-Breaking Abstract (LBA 9509): GC101 met its primary endpoint with a 42% ORR and 4.3-month median PFS (HR 0.43, p=0.0002 vs chemotherapy). Zero treatment-related deaths were observed. Study enrolled 98 patients, 81.8% with acral or mucosal melanoma. Full report →
| Endpoint | GC101 TIL (n=49) | Chemotherapy (n=49) |
|---|---|---|
| Objective Response Rate (ORR) | 42.0% | 6.1% |
| Median Progression-Free Survival (PFS) | 4.3 months | 1.6 months |
| Hazard Ratio (95% CI) | 0.43 [0.28–0.65], p=0.0002 | |
| 6-month PFS rate | 36.0% | 8.0% |
| Disease Control Rate (DCR) | 72.0% | 24.5% |
| Complete Response (CR) | 8.2% | 0% |
| Treatment-related deaths | 0 | 0 |
| As reported at ASCO 2026, LBA 9509. Presented by Dr. Lu Si; PI Prof. Jun Guo. Single-trial analysis — confirmatory studies needed. | ||
In the completed Phase I trial, GC101 demonstrated a 34.8% ORR and 78.3% DCR across multiple solid tumors including melanoma. Three patients achieved complete responses — the longest disease-free survival exceeding two years and ongoing at data publication.
Important distinction: Unlike Iovance's lifileucel trial (enrolled predominantly cutaneous melanoma), MIZAR-003 specifically includes acral and mucosal subtypes. Despite a more challenging patient population, GC101 demonstrated comparable or superior efficacy.
The most significant safety advantage of GC101 is the elimination of lymphodepletion conditioning chemotherapy. Traditional TIL protocols require high-dose chemotherapy (cyclophosphamide + fludarabine) causing severe bone marrow suppression and infections. With GC101, the TIL infusion can be administered in a general hospital ward. The most common adverse events — fever, rash, chills — are mild to moderate and resolve with standard symptomatic treatment. Zero treatment-related deaths have been observed across all clinical trials to date.
These cases from the GC101 clinical program illustrate the potential of TIL therapy in advanced melanoma patients who had exhausted all other treatment options.
A female patient in her 50s with acral melanoma on the left elbow and lymph node metastases. After all standard therapies failed to control the disease, she received a single GC101 infusion. At 6 weeks, imaging showed significant tumor shrinkage. By 8 months, imaging confirmed complete metabolic response — no active disease. She returned to normal work, with ongoing disease-free status beyond 2 years.
A female patient with acral melanoma on the right foot (2018) with recurrence in 2024 including lung, pleural, and peritoneal metastases. The primary foot lesion grew to ~9 cm despite two lines of therapy including PD-1 and dual immunotherapy. After GC101 infusion, 18-week evaluation showed partial response: lung lesion reduced by 47.4%, peritoneal lesion by 31.7%, foot lesion by 36.0%. Only mild immune-related symptoms were observed.
Note on subtypes: MIZAR-003 includes acral and mucosal subtypes — unlike US-approved lifileucel which enrolled predominantly cutaneous melanoma. If you have acral or mucosal melanoma that has failed PD-1 therapy, GC101 may be one of the few effective options available.
Submit your medical records for review. CancerPath assesses eligibility at no cost.
A small tumor tissue sample is collected via minimally invasive procedure.
TIL cells are expanded at Juncell's GMP facility using the DeepTIL platform.
Return to Hainan Boao Lecheng medical zone for the infusion procedure.
CancerPath coordinates remote imaging follow-up and ongoing support.
| Factor | GC101 (China) | Iovance Lifileucel (US) |
|---|---|---|
| Approved subtypes | All incl. acral, mucosal | Cutaneous primarily |
| Overall ORR | 42% (Phase II RCT) | 31-36% |
| Lymphodepletion | No | Yes — high-dose chemo |
| IL-2 support | No | Yes — high-dose IL-2 |
| ICU stay | No | Often required |
| Estimated cost | ~$110,000 | $515,000+ |
Acral melanoma occurs on non-sun-exposed areas — palms, soles, under nails. These subtypes have lower tumor mutational burden, making them less visible to PD-1 checkpoint inhibitors. This is why standard immunotherapy is less effective for these subtypes.
In the MIZAR-003 Phase II trial, GC101 achieved 42% ORR in advanced melanoma including acral and mucosal subtypes. The median PFS was 4.3 months vs 1.6 months with chemotherapy (HR 0.43, p=0.0002).
Free consultation → tissue collection in Shanghai (2-3 days) → cell manufacturing at home (4-6 weeks) → infusion in Hainan (3 days) → remote follow-up. Requires two short trips to China totaling ~5-6 days on the ground.
GC101's safety profile is significantly better than conventional TIL therapy. No lymphodepletion, no high-dose IL-2, no treatment-related deaths. Common adverse events are mild to moderate (fever, chills, rash) and resolve with standard treatment.
MIZAR-003 is led by Prof. Jun Guo (郭军) at Peking University Cancer Hospital. Prof. Guo is Vice President of CSCO, Chairman of the CSCO Melanoma Expert Committee, and Vice President (Asia) of the Melanoma World Society (MWS).
If you have advanced melanoma that has progressed after PD-1 therapy, GC101 TIL therapy may offer a path forward. Request a free eligibility assessment today.
Email clinicaltrials@juncell.com →